<DOC>
	<DOCNO>NCT00823225</DOCNO>
	<brief_summary>The purpose study determine whether additional therapy low dose urokinase effective conventional standard therapy concern ulcer-healing , rate major amputation survival .</brief_summary>
	<brief_title>Urokinase Therapy Patients With Diabetic Foot Syndrome</brief_title>
	<detailed_description>Patients diabetic foot ulceration critical limb ischemia high risk major amputation , especially limbs revascularized . Urokinase effective critical limb ischemia lower fibrinogen might improve outcomes . The effect safety urokinase treatment investigate phase II clinical trial . Based result trial planned investigate effect safety additional therapy urokinase versus single conventional therapy .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Diabetic patient angiopathic angioneuropathic diabetic foot syndrome criticial limb ischemia No surgical interventional treatment option No healing tendency ulceration despite antibiosis wound debridement twoweek treatment Fibrinogen &gt; 4.0 g/l No previous major amputation Prior treatment current ulceration urokinase Need dialysis and/or creatinineclearance &lt; 20ml/min INR &gt; 1,5 screen Any kind cerebral event within 3 month prior inclusion Proliferative retinopathy Uncontrolled hypertension Hemorraghic diathesis Gastrointestinal bleeding Pregnancy No compliance and/or participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>urokinase</keyword>
	<keyword>ulcer heal</keyword>
	<keyword>major amputation</keyword>
	<keyword>survival</keyword>
</DOC>